J&J: RYBREVANT + Chemotherapy Shows Strong Benefits And Improved Survival In Phase 3 NSCLC Trial
14/9 09:54
(RTTNews) - Johnson & Johnson (JNJ) announced that updated results from the Phase 3 MARIPOSA-2 study showed that combining RYBREVANT (amivantamab-vmjw) with chemotherapy provided consistent benefits across post-progression outcomes for adult patients with previously treated non-s...